Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
about
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationA mechanistic tumor penetration model to guide antibody drug conjugate designWorld Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development.Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage PredictionsEmerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic modelPhysiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia TherapyBiodistribution of etanercept to tissues and sites of inflammation in arthritic rats.Antibody Drug Conjugates: Nonclinical Safety Considerations.Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in RatsA physiologically based pharmacokinetic model of rifampin in mice.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancerSecond-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Review on modeling anti-antibody responses to monoclonal antibodies.Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Challenges and considerations for development of therapeutic proteins in pediatric patients.Assessments of antibody biodistribution.Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review.Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Influence of Molecular size on the clearance of antibody fragments.Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide.Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Quantification of IgG monoclonal antibody clearance in tissues.Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
P2860
Q28082880-24190D08-7577-434B-A4D0-8D902BFB1408Q28088352-AB85F3CF-95DF-4287-BB95-8AA51C824F3DQ28544636-ACC539E7-ABF6-4093-A497-728FE5A1581DQ30414399-656F857B-B3A9-4328-BF0D-3802F71EEB84Q30930928-115F3AF7-AB53-45ED-8202-EE1DA34F29C5Q30988835-EBF34F3D-DBF0-422D-BDE9-C29884693E6AQ31138430-8E6346FF-9161-4D53-8E58-F1C71467D8BEQ33838871-0027D669-4254-4871-9087-7C188C3995C3Q34099756-F2FB4063-ADAE-456D-B452-1A806B2030CEQ34204024-CD8418D6-49A7-4299-BE52-5AA6DD7DBB4DQ34484225-0757F109-938C-44FC-9BB1-8184A4BA4408Q35382898-BCC07703-4EA6-47DF-AB08-DF533632FA54Q35600264-8AE9280E-B9D5-4E46-81A6-07A541101F13Q35967917-C23ED890-4F3D-40FE-B79A-D18249085596Q36087076-1EC73B35-8151-4D06-BEB9-560539ED5207Q36232508-59E4D6E2-0D7B-483F-B03B-369057FDD02BQ36757635-1B7B0C61-BA0F-4C9D-8417-34336D5C6FA6Q36910606-697429E6-208F-4A7C-B42D-544F14837896Q37054801-62436B23-8A64-429A-B35C-A609AFA38EB1Q37331009-C7B0DB51-8DFA-4695-BAA3-4B6E9D6F7D80Q37609774-5FC60E3F-82E3-4BB3-81C6-71990F932AFCQ38061684-E641A1B0-32A4-499A-943C-201395BA51E5Q38072598-F4D0359F-67D5-48A8-9EAD-71CEBE6BC6C3Q38128342-7600758A-C759-4A9B-BBBB-481AD0EC3C30Q38229813-4C23D4A7-AF3C-4EB3-AD39-FE9BF53FCA95Q38350045-35B88F18-AFE0-45A8-9955-B3EA8753260BQ38351385-95668EAB-4E21-425C-B7A3-4D3D0B912A0EQ38364457-CF215C6D-98D6-4F27-A1DE-F799699EDD33Q38364460-0B5F43FA-5373-482E-95DA-FA46FD4A53C5Q38502414-9B074461-13DF-4338-9EA3-9344CCEC20AAQ38557522-A2F17B78-63EA-439E-9155-8FAD50C09CDBQ38587550-75328C91-9D45-46D1-8770-476B206D56D1Q38605894-E3C1E044-8FF9-4591-82C9-3E1535EE3B0BQ38624597-AF5F92D1-9DF5-4EFB-8351-5EC832E1FFFFQ38691818-FF57A409-562F-4A47-99AE-094481CEB0DCQ38705177-600FDE3C-C597-4E5E-864A-AB554734670CQ38707798-5E41067C-7582-4959-B82D-AEC14D5C7A62Q38714339-01E49C59-078B-404B-8A43-2895829B085AQ38726179-531DAD57-65AF-4A4A-BD1F-8A16AA31CCC4Q38765188-CF9B9A7F-03FF-4CBC-AA3B-FFA4EA18872C
P2860
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Towards a platform PBPK model ...... preclinical species and human.
@en
Towards a platform PBPK model ...... preclinical species and human.
@nl
type
label
Towards a platform PBPK model ...... preclinical species and human.
@en
Towards a platform PBPK model ...... preclinical species and human.
@nl
prefLabel
Towards a platform PBPK model ...... preclinical species and human.
@en
Towards a platform PBPK model ...... preclinical species and human.
@nl
P2860
P1476
Towards a platform PBPK model ...... preclinical species and human.
@en
P2093
Alison M Betts
Dhaval K Shah
P2860
P2888
P356
10.1007/S10928-011-9232-2
P577
2011-12-06T00:00:00Z